Background

Background

The manufacturer of canakinumab (Novartis) was invited to submit evidence for the single technology appraisal of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks.

The manufacturer informed NICE that it would not be making an evidence submission for this appraisal. The manufacturer stated that it will not be promoting canakinumab for this specific indication in the UK.

NICE has therefore terminated this single technology appraisal.

  • National Institute for Health and Care Excellence (NICE)